• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

What is ALS/MND?

Motor Neurone Disease (MND) is the name given to a group of diseases in which the nerve cells (neurones) that control muscles undergo degeneration and die. Amyotrophic Lateral Sclerosis (ALS), Progressive Muscular Atrophy (PMA), Progressive Bulbar Palsy (PBP), and Primary Lateral Sclerosis (PLS) are all subtypes of motor neurone disease.

MND is the widely used generic term in the United Kingdom, Australia, and parts of Europe, while ALS is used more generically in the United States, Canada, and South America.

These diseases are also sometimes known as Maladie de Charcot and are often referred to in the United States as Lou Gehrig’s Disease, after the famous baseball player who died of the disease.

How Does ALS/MND Affect the Body?

By any name, ALS/MND is characterised by progressive degeneration of the motor nerve cells in the brain and spinal cord. The motor cells (neurones) control the muscles that enable us to move around, speak, breathe, and swallow.

With no nerves to activate them, muscles gradually weaken and waste. Symptoms may include muscle weakness and paralysis, as well as impaired speaking, swallowing, and breathing. Progress is generally rapid, with an average life expectancy of between 2 and 5 years from the onset of symptoms.

Though it can affect anyone, ALS/MND is more often found in the 40 to 70 year age group.

How Common Is ALS/MND?

The impact of ALS/MND on the community is usually measured by incidence and prevalence. Incidence is the number of new cases diagnosed during a defined period, usually a year. Prevalence is the number of people living with the disease at a given point in time.

2 per 100,000

Incidence
New cases diagnosed each year

6 per 100,000

Prevalence
People living with ALS/MND

~140,000

New cases worldwide
Approximately each year

Research has found that incidence is higher in people aged over 50 years. Although classified as a rare disease based on its prevalence, ALS/MND is, in fact, quite common. Approximately 140,000 new cases are diagnosed worldwide each year — about 384 every day.

Genetics and ALS/MND

A small proportion of cases (~10%) are familial (inherited), while the majority of cases (~90%) are still considered sporadic or singleton. However, research continues to reveal genetic associations with ALS/MND.

This may mean that many cases currently considered sporadic also have a genetic contribution. Further research is needed to establish the extent to which genetics contributes to causing and/or moderating ALS/MND.

The Alliance believes that all people diagnosed with ALS/MND should have access to genetic counselling and testing if they choose to.

Living with ALS/MND

The disease affects each individual differently and can have a devastating impact on family, carers, and friends. The rapidly progressive nature of the disease requires constant adaptation to increasing and changing levels of disability, which in turn require increased levels of support.

Find Information and Support in Your Region

For information about ALS/MND in other languages, or to connect with an ALS/MND organization in your region, visit our Member Association directory.

Find a Member Association

Primary Sidebar

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Paul Launer, USA

    Paul Launer, USA

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Graham Johnson, Australia

    Graham Johnson, Australia

  • Daniel Hare, USA

    Daniel Hare, USA

  • David Bishop, UK

    David Bishop, UK

  • Ana María Zavala, Mexico

    Ana María Zavala, Mexico

  • Richard Clark, New Zealand

    Richard Clark, New Zealand

  • Ailsa Malcolm-Hutton, UK

    Ailsa Malcolm-Hutton, UK

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • Inta Grubb, Australia

    Inta Grubb, Australia

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Chris McCauley, Canada

    Chris McCauley, Canada

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Laurie Petit-Jean, France

    Laurie Petit-Jean, France

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Greg Heydet, USA

    Greg Heydet, USA

  • Dr. Janmejay Pradhan, India

    Dr. Janmejay Pradhan, India

  • John Dinon, Australia

    John Dinon, Australia

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Lachlan Terry, Australia

    Lachlan Terry, Australia

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Chen Chun-Chin, Malaysia

    Chen Chun-Chin, Malaysia

  • David Solomon, UK

    David Solomon, UK

  • Phil Rossall, UK

    Phil Rossall, UK

  • Angie Bordaen, Belgium

    Angie Bordaen, Belgium

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Philip Brindle, England

    Philip Brindle, England

  • Brian Lovell, Australia

    Brian Lovell, Australia

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Peng Yi-Wen, Taiwan

    Peng Yi-Wen, Taiwan

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Rosie Riley, USA

    Rosie Riley, USA

  • Barry de Reuver, Netherlands

    Barry de Reuver, Netherlands

  • Jean

    Jean
    jean

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Yolanda Armendariz, Mexico

    Yolanda Armendariz, Mexico

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Lombana, Spain

    Lombana, Spain

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Steve

    Steve

  • Torben Mikkelsen, Denmark

    Torben Mikkelsen, Denmark

  • Timmy, Belgium

    Timmy, Belgium

  • Christian Bär, Germany

    Christian Bär, Germany

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login